54 results about "Homeobox" patented technology

Methods are described that bias cells, such as potent and multipotent stem cells, by transfection with a nucleic acid sequence, to differentiate to a desired end-stage cell or a cell having characteristics of a desired end-stage cell. In particular embodiments, human neural stem cells are transfected with vectors comprising genes in the homeobox family of transcription factor developmental control genes, and this results in a greater percentage of resultant transformed cells, or their progeny, differentiating into a desired end-stage cell or a cell having characteristics of a desired end-stage cell.

The present invention embraces microRNA-antagonists and activators of homeobox D10 protein; Zinc finger, MYND domain containing 11 protein; or RB1-inducible coiled-coil 1 protein for use in decreasing glial tumor cell proliferation and treating glioma.

The disclosure pertains to methods and compositions for the rapid and efficient transformation of plants. The disclosure further provides methods for producing a transgenic plant, comprising (a) transforming a cell of an explant with an expression construct comprising (i) a nucleotide sequence encoding a WUS/WOX homeobox polypeptide; (ii) a nucleotide sequence encoding a polypeptide comprising twoAP2-DNA binding domains; or (iii) a combination of (i) and (ii); and (b) allowing expression of the polypeptide of (a) in each transformed cell to form a regenerable plant structure in the absence ofexogenous cytokinin, wherein no callus is formed; and (c) germinating the regenerable plant structure to form the transgenic plant. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

Plants having enhanced yield-related traits and a method for making the same The present invention relates generally to the field of molecular biology and concerns a method for enhancing various economically important yield-related traits in plants. More specifically, the present invention concerns a method for enhancing yield-related traits in plants by modulating expression in a plant of a nucleic acid encoding a HSFA4 or HSFA5 (Heat Shock Factor of the class A4 or A5) polypeptide. The present invention also concerns plants having modulated expression of a nucleic acid encoding a HSFA4 or a HSFA5 polypeptide, which plants have enhanced yield-related traits relative to control plants. The invention also provides constructs comprising the same, useful in performing the methods of the invention. Furthermore, the present invention relates generally to the field of molecular biology and concerns a method for enhancing various yield-related traits by modulating expression in a plant of a nucleic acid encoding an oligopeptide transporter protein (OPT4-like) polypeptide. The present invention also concerns plants having modulated expression of a nucleic acid encoding an OPT4-like polypeptide, which plants have enhanced yield-related traits relative to corresponding wild type plants or other control plants. The invention also provides constructs useful in the methods of the invention. The invention also provides hitherto unknown OPT4-like-encoding nucleic acids, and constructs comprising the same, useful in performing the methods of the invention. Furthermore, the present invention relates generally to the field of molecular biology and concerns a method for enhancing various yield-related traits by modulating expression in a plant of a nucleic acid encoding a plastochron2-like (PLA2-like) polypeptide. The present invention also concerns plants having modulated expression of a nucleic acid encoding a PLA2-like polypeptide.

Methods for modulating plants using optimized ZmME293 down-regulation constructs are disclosed. Also disclosed are nucleotide sequences, constructs, vectors, and modified plant cells, as well as transgenic plants displaying increased seed and/or biomass yield, improved tolerance to abiotic stress such as drought or high plant density, improved nitrogen utilization efficiency, increased ear number and/or reduction in time to scenescence.

The invention discloses a Pif promoter capable of being activated by pinctada martensii MSX (muscle segment homeobox) genes and application of the Pif promoter. The nucleotide sequence of the Pif promoter is shown as SEQ ID NO.1. A Pif promoter sequence is obtained through amplification by a genome walking method. The Pif promoter has a binding site 1 and a binding site 2, which can be bound to the MSX genes. Through the establishment of wild type carriers and mutant type carriers of Pif promoters of different fragment lengths, a dual-luciferase reporter gene system is applied to identify the fact that the MSX genes act on the Pif promoter through the binding site 1. The Pif promoter can start the downstream target gene expression, thereby promoting the growth of pearls or pearl oysters.

The invention discloses alleles for regulating and controlling two types of main stem table fur types of upland cotton, and a single stranded conformational polymorphism (SSCP) molecular marker for identification thereof. On the research basis of defining that an HDI gene in a homeobox-homeodomain-leucine zipper protein family IV is a key gene of affecting table fur generation of the upland cotton, the alleles GhHD1a and b for regulating and controlling regeneration of two types of stem table furs of the upland cotton are identified for the first time; a molecular marker for screening the two alleles by using the SSCP technology is invented. The molecular marker can rapidly identify two kinds of table fur types. The alleles prove that two genetypes of the HD1 have close relationship to two table fur types, a foundation is established for researching the molecular mechanism of generating table furs and fibers, the deoxyribonucleic acid (DNA) molecular marker capable of directly identifying the table fur type of the upland cotton in a laboratory is developed, and a rapid technology is provided for rapidly breeding different fur types of new cotton varieties.

The present invention relates to a novel member of the NK family of homeobox genes. In particular, isolated nucleic acid molecules are provided encoding the human NK-3 prostate specific gene 1 (NKX3.1) protein. NKX3.1 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of NKX3.1 activity. Also provided are diagnostic methods for detecting prostate cancer and other cancers and therapeutic methods for prostate cancer and other cancers.

The present invention relates to the field of gastric cancer. More specifically, the present invention provides methods and compositions for diagnosing and treating gastric cancer. In a specific embodiment, a method for diagnosing gastric cancer or a likelihood thereof in a patient comprises the steps of (a) providing a sample from the patient; (b) measuring the methylation levels of one or more biomarkers in the sample collected from the patient; and (c) predicting gastric cancer in the patient if the biomarkers are hypermethylated. In a more specific embodiment, the one or more biomarkers comprises tight junction protein claudin-1 1 (CLD-N11), the transcription factor BarH-like homeobox (BARX1), basonuclin1 (BNC1), Coagulation factor C homolog (COCH), filamin C gamma (FLNC), cytoglobin B (CYGB), glutamine-fructose-6-phospahe-transaminase-2 (GFPT2), heat-shock-70 kDa protein-6 (HSPA6), snail homolog 1(SNAL1), skin calmodulin-related factor (SCARF), and tumor protein p53 binding protein 2 (TP53BP2).

A method of treating a cancer, the method comprising: providing a genetically modified macrophage or monocyte that contains a nucleic acid sequence encoding a Hom-1 polypeptide or a fragment thereof that contains the Hom-1 homeobox domain, wherein the nucleic acid sequence is operably linked to a heterologous promoter and the modified macrophage or monocyte expresses the Hom-1 polypeptide or the fragment thereof; and administering the modified macrophage or monocyte to a subject with a cancer.

The invention discloses applications of ZEB1 (zinc finger E-box binding homeobox 1) in human cardiac fibroblasts. According to the applications, ZEB1 is adopted as the research object, ZEB1 interference small fragments are synthesized for transfecting the cardiac fibroblasts, the result shows that ZEB1 promotes the proliferation, migration, differentiation and collagen synthesis of the cardiac fibroblasts, and research is further carried out by controlling the functions of miR-590-3p expressed by ZEB1 in the cardiac fibroblasts. After interference of ZEB1, the verification shows that the cellfunction phenotype caused by miR-590-3p can restore, which proves that ZEB1 is an important function target of miR-590-3p in the cardiac fibroblasts, and miR-590-3p can regulate the functions of the fibroblasts through ZEB1. Through the applications of ZEB1 and the ZEB1-targetting miRNA in the cardiac fibroblasts, a very good application value is achieved for researching the fibrosis mechanism after myocardial infarction.

The invention belongs to the technical field of medicines, and particularly relates to a targeting inhibitor of an RAX2 (Retina and Anterior Neural Fold Homeobox 2) gene and a purpose thereof. According to the targeting inhibitor of the RAX2 gene, the gene sequence of the targeting inhibitor is 5'-GGAGGAACCGCACCACCTTCATTCAAGAGA-3' (SEQ ID No. 1). The inhibitor can be specifically bound with the RAX2 gene; the RAX2 gene is silenced; thus, the influences, on the cell proliferation, migration and invasion ability of a glioma, of an RAX2 are inhibited; the cell apoptosis of the glioma is induced and the goal of treating the glioma is realized.

The invention relates to a unique formulated pharmaceutical composition and a novel treatment method of intratumoral injection. The pharmaceutical composition of the invention is the saturated ionic solution of sodium ions and calcium ions (the “medicinal ion bomb”). The invention of intratumoral injection with the “medicinal ion bomb” can be used as the first-line treatment in treating cancer and tumor in nine human organs (carcinoma and tumor of the skin and subcutaneous tissue, breast, prostate, thyroid, lung, liver, genital organ, brain and pancreas) and certain other benign diseases (skin and subcutaneous neoplasm, breast fibrocystic change, benign prostatic hyperplasia and thyroid nodules).

The invention relates to inhibitory Nanog mutant which is obtained by changing nuclear localization signals 1 and/or 2 positioned in Nanog conservative structure domain Homeobox (the sequence is seen in SEQ ID NO: 2) to damage the functions, wherein the mutant still has the capability of forming heterodimer with wild type Nanog, and inhibits the function of transcriptional activation of wild type Nanog and the function is brought into play as inhibitory Nanog mutant, thereby being capable of being used as a very useful inhibitory tool to research the function of mouse Nanog.

The invention generally relates to human biology discoveries and therapeutic and diagnostic compositions and methods based thereon. More particularly, the invention relates to human homeobox gene VentX and its control of macrophage terminal differentiation and activation, and related therapeutic and diagnostic compositions and methods of use, in particular in connection with inflammatory diseases.